Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors

November 15th 2024

The CHMP has recommended repotrectinib for ROS1-positive non–small cell lung cancer and NTRK-positive solid tumors.

CHMP Recommends First-Line Pembrolizumab Plus Chemo for Unresectable Non-Epithelioid Malignant Pleural Mesothelioma

November 15th 2024

The CHMP has recommended the approval of pembrolizumab plus chemotherapy for first-line unresectable non-epithelioid malignant pleural mesothelioma.

Isatuximab Plus VRd Earns CHMP Recommendation for Newly Diagnosed, Transplant-Ineligible Myeloma

November 15th 2024

The CHMP has recommended the EU approval of isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma.

CHMP Recommends Approval of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC

November 15th 2024

The EMA’s CHMP agency recommended approval for nivolumab plus ipilimumab in patients with MSI-H/dMMR unresectable or metastatic colorectal cancer.

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

November 15th 2024

Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.

GRANITE Plus ICIs and Bevacizumab/Chemo Shows Improved PFS Trend in MSS mCRC

November 15th 2024

GRANITE-based maintenance therapy improved PFS in first-line MSS colorectal cancer.

Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making

November 14th 2024

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

November 14th 2024

Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML

November 14th 2024

The FDA has approved nilotinib tablets without mealtime restrictions for select patients with chronic myeloid leukemia.

2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More

November 14th 2024

Yelena Y. Janjigian, MD, highlights key takeaways and data from 2024 in the gastric and GEJ cancer field.

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers

November 14th 2024

Sacituzumab tirumotecan monotherapy demonstrated antitumor activity with a manageable safety profile in previously treated endometrial and ovarian cancers.

NXP800 Demonstrates Single-Agent Activity in ARID1a+ Platinum-Resistant Ovarian Cancer

November 14th 2024

NXP800 generated antitumor activity as monotherapy in platinum-resistant ovarian cancer harboring ARID1a mutations.

Eftilagimod Alpha Plus Pembrolizumab/Chemo Generates Improved Survival Trends in Advanced NSCLC

November 14th 2024

Eftilagimod alpha plus pembrolizumb and chemotherapy generated favorable survival data in nonsquamous NSCLC.

Belantamab Mafodotin Plus Bortezomib/Dexamethasone Extends OS in R/R Myeloma

November 14th 2024

Belantamab mafodotin plus bortezomib and dexamethasone met the key secondary end point of OS in relapsed/refractory multiple myeloma in the DREAMM-7 study.

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma

November 14th 2024

Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.

Clinical Oncology Bridges Gaps Between Medical Oncology, Radiation Oncology, and Clinical Research: With D. Ross Camidge, MD, PhD; and Duncan McLaren, MBBS, BSc, FRCR, FRCP

November 13th 2024

Drs Camidge and McLaren discuss Dr McLaren’s journey to medical school and his experience as a clinical oncologist with expertise across disciplines.

177Lu-PSMA-I&T Meets rPFS End Point in PSMA+ mCRPC

November 13th 2024

177Lu-PSMA-I&T improved radiographic progression-free survival vs hormonal therapy in PSMA-positive metastatic castration-resistant prostate cancer.

Retrospective Data Show Pacritinib Improves TSS in Transfusion-Dependent Myelofibrosis

November 13th 2024

A retrospective study showed pacritinib improved symptoms in transfusion-dependent myelofibrosis.

IBI354 Shows Efficacy and Safety in HER2+ and HER2-Low Advanced Breast Cancer

November 13th 2024

IBI354 showed favorable safety and efficacy in patients with advanced HER2-positive and HER2-low breast cancer.

FDA Receives New BLA for Dato-DXd in Pretreated EGFR+ Advanced NSCLC

November 12th 2024

AstraZeneca has filed a new BLA for Dato-DXd in pretreated, EGFR-mutated advanced non–small cell lung cancer.